No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OII Oceaneering International
- 23.180
- -1.100-4.53%
Close May 22 16:00 ET
2.35BMarket Cap21.87P/E (TTM)
24.180High23.070Low1.22MVolume24.170Open24.280Pre Close28.34MTurnover1.22%Turnover Ratio24.40P/E (Static)101.39MShares27.46052wk High3.77P/B2.31BFloat Cap14.99052wk Low--Dividend TTM99.64MShs Float79.892Historical High--Div YieldTTM4.57%Amplitude1.929Historical Low23.312Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Calculating The Intrinsic Value Of Oceaneering International, Inc. (NYSE:OII)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Oceaneering International fair value estimate is US$26.02 Current share price of US$24.28 suggests Oceaneering International is potentially t
The Return Trends At Oceaneering International (NYSE:OII) Look Promising
Expro Upgraded, Oceaneering Cut at Barclays, With TechnipFMC Top Pick in Offshore
Express News | Oceaneering International Shares Are Trading Lower After Barclays Downgraded the Stock to Underweight
Decoding 5 Analyst Evaluations For Oceaneering International
In the preceding three months, 5 analysts have released ratings for Oceaneering International (NYSE:OII), presenting a wide array of perspectives from bullish to bearish.The following table encapsulat
Express News | Oceaneering International : Barclays Cuts to Underweight From Equal-Weight
Comments
The modest level of insider ownership and lack of insider transactions in the last three months suggest alignment with shareholder interests. However, significant insider selling over the past year could be a red flag for investors.
Insiders At Oceaneering International Sold US$2.5m In Stock, Alluding To Potential WeaknessOceaneering International, Inc.'s transition from loss to profitability justifies its strong share price gain. Despite slowing gains, the company's future financial health remains crucial for shareholders.
Oceaneering International's respectable ROE is overshadowed by its high debt level. Investors should consider the company's performance potential in less favorable credit markets. High ROE without debt typically indicates a high-quality business.
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
17
7
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg